Search
sodium phenylbutyrate/tauroursodeoxycholic acid; sodium phenylbutyrate/taurursodiol (Relyvrio, AMX0035)
Indications:
- investigational treatmment for amyotrophic lateral sclerosis (ALS)
* failed ALS drug, pulled from U.S. & Canadian market
Clinical significance:
- median time to first hospitalization > 64 weeks (median time for placebo)
- median time to death or need for tracheostomy/permanent assisted ventilation 104 weeks vs 80 weeks for placebo [2]
General
pharmacologic combination
neurologic agent
Database Correlations
PUBCHEM cid=129316491
References
- Paganoni S
Trial of Sodium Phenylbutyrate - Taurursodiol for Amyotrophic Lateral Sclerosis.
N Engl J Med 2020; 383:919-930. Sept 3
PMID: 32877582
https://www.nejm.org/doi/full/10.1056/NEJMoa1916945
- George J
Early Data for ALS Drug Show Survival Benefit -
Mortality cut 44% over follow-up period
MedPage Today October 16, 2020
https://www.medpagetoday.com/neurology/generalneurology/89172
- Susman E
Novel ALS Drug Continues to Show Survival Benefit.
Median time to first hospitalization not yet reached with AMX0035 in CENTAUR trial.
MedPage Today. April 19, 2021
https://www.medpagetoday.com/meetingcoverage/aan/92166
- Paganoni S et al
Long-term survival of participants in the CENTAUR trial of AMX0035 for ALS.
American Academy of Neurology (AAN) 2021
- Bagha S
Amylyx pulls ALS drug Relyvrio from market in US, Canada.
Healio. April 4, 2024
https://www.healio.com/news/neurology/20240404/amylyx-pulls-als-drug-relyvrio-from-market-in-us-canada
Components
phenylbutyrate (Buphenyl, Olpruva)
tauroursodeoxycholic acid; tauroursodeoxycholate; taurursodiol; taurolite